B. Braun Thailand signs MoA with Ramathibodi Comprehensive Cancer Center to share expertise on ambulatory home-based chemotherapy care via Aesculap Academy
We share expertise, to improve and enhance the quality of life for cancer patients.
(From left to right)
Kanokkarn Kham-Orn, R.Ph, Deputy Division Head – Commercial Excellence, Ms. Jesmine Khoo, Chief Financial Officer - Finance & IT, Mr. Sayan Roy, Managing Director of B. Braun Thailand, Assoc. Prof. Ekaphop Sirachainan, MD., Chairman of Ramathibodi Comprehensive Cancer Center), Assoc. Prof. Surasak Leela-Udomlipi, M.D., Director and Phichai Chansriwong, M.D., Oncologist, Faculty of Medicine Ramathibodi Hospital
Bangkok, Thailand - 21st August, 2023 - B. Braun (Thailand) Ltd., the world’s leading medical technology company from Germany, signed a Memorandum of Agreement (MoA) with the Ramathibodi Comprehensive Cancer Center (RCCC), Faculty of Medicine Ramathibodi Hospital, Mahidol University, to collaborate on developing educational programs on ambulatory home based-chemotherapy model, which can be applied and practiced in healthcare settings to enhance the capacity of healthcare professional. Signing on behalf of B. Braun (Thailand) Ltd., is its Managing Director Mr. Sayan Roy, while signing on behalf of RCCC is Assoc. Prof. Ekaphop Sirachainan, M.D., Chairman of RCCC and Phichai Chansriwong, M.D., Oncologist, Faculty of Medicine Ramathibodi Hospital. Also present was Assoc. Prof. Surasak Leela-Udomlipi, M.D., Director of Ramathibodi Hospital, who delivered the welcome speech.
The development of professional competence in the field of ambulatory home-based chemotherapy is a vital part of improving caregiving and cancer patient outcomes. This collaboration will serve to elevate the standard guidelines on developing home based-chemotherapy model at the workplace for healthcare personnel in Asia Pacific and enhance their skills and capabilities through various training programs.
This signing of the MoA reinforces B. Braun’s commitment of Sharing Expertise through our Aesculap Academy, a leading medical education arm that is dedicated to strengthening the skills of healthcare professionals, as we strive to protect and improve the health of people around the world.
Assoc. Prof. Ekaphop Sirachainan, MD., Chairman of Ramathibodi Comprehensive Cancer Center said, “On behalf of the Ramathibodi Comprehensive Cancer Center, Faculty of Medicine Ramathibodi Hospital, we are delighted to be involved with B. Braun Thailand and Aesculap Academy in signing the MoA to develop the education program about ambulatory home-based chemotherapy service to healthcare personnel and nurses from various hospitals in Asia Pacific. RCCC has been establishing in 2014, we and B. Braun Thailand has always been fostered long-term connections since then. The collaboration on education program could expand the knowledge on home-based chemotherapy treatment and solve the delayed chemotherapy schedule for cancer patients because of insufficient hospital bed as well as cost saving. Cancer patients treated by home chemotherapy would receive the good results which are not different from the normal treatment like drug administration. Also, it can save cost and patients would become the better quality of life. We expected that the education would enhance all attendees and would be a guideline for international practice in the future.”
Mr. Sayan Roy, Managing Director, B. Braun (Thailand) Ltd. said, “We are honored to partner with the esteemed Ramathibodi Comprehensive Cancer Center, as we work together to advance cancer treatment and improve the health of patients across the world. This collaborative effort reflects our shared belief in the transformative power of exchanging knowledge and sharing expertise. Through this partnership, we are committed to creating meaningful opportunities for healthcare professionals and patients alike. As a leading medical device company, partnering with experts, this collaboration will drive effective improvements in education and hence cancer treatments across the region. Our ultimate goal is to advance cancer treatment and ideally enhance the quality of life for patients.”
The signing ceremony event was honored by representatives from the Ramathibodi Comprehensive Cancer Center and management team from B. Braun (Thailand) Ltd., this is reaffirming our commitment toward vision “To protect and improve the health of people around the world”.
About B. Braun
As one of the world’s leading medical technology companies, B. Braun aims to protect and improve the health of people around the world. For more than 180 years, we have shaped health care with our pioneering spirit and groundbreaking contributions. Through Sharing Expertise and the power of technology we drive advancements in health care. With more than 65,000 employees in 64 countries, we develop smart solutions as a true partner and set standards to improve health care.
About B. Braun Thailand
B. Braun was established in Thailand in 1989, and continues till today to support healthcare professionals across the country. Along with our Renal Care centers and Technical Service center, we also advance education for medical practitioners through our world-renowned Aesculap Academy.
With a strong our Code of Conduct and a commitment towards Sustainability, B. Braun Thailand has been named HR Asia’s “Best Companies to work for in Asia” for three consecutive years (2020-2022).
About Aesculap Academy
The Aesculap Academy® connects people who want to develop their skills in the healthcare sector with aim to empower the individuals that work in this sector with innovative, real-life and life-long education concepts. These concepts comprise cutting-edge research, improved simulation, insightful training, and significant content that shapes the future of medical care worldwide.
Established within the B. Braun Group since 1995, the Aesculap Academy is recognized as a symbol in medical education, connecting healthcare professionals worldwide through advances in new technologies and methods so that they can exchange insights across its global network.